S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:STRO

Sutro Biopharma (STRO) Stock Price, News & Analysis

$3.63
-0.14 (-3.71%)
(As of 04/19/2024 ET)
Today's Range
$3.55
$3.80
50-Day Range
$3.27
$5.65
52-Week Range
$2.01
$6.13
Volume
515,911 shs
Average Volume
1.39 million shs
Market Capitalization
$226.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.57

Sutro Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
246.3% Upside
$12.57 Price Target
Short Interest
Healthy
3.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.67mentions of Sutro Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$60,925 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.18) to ($2.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.75 out of 5 stars

Medical Sector

55th out of 909 stocks

Biological Products, Except Diagnostic Industry

7th out of 149 stocks

STRO stock logo

About Sutro Biopharma Stock (NASDAQ:STRO)

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

STRO Stock Price History

STRO Stock News Headlines

The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Navigating 4 Analyst Ratings For Sutro Biopharma
TD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)
See More Headlines
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/25/2024
Today
4/21/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
302
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.57
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+246.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-106,790,000.00
Pretax Margin
-57.63%

Debt

Sales & Book Value

Annual Sales
$153.73 million
Book Value
$2.46 per share

Miscellaneous

Free Float
58,134,000
Market Cap
$226.66 million
Optionable
Optionable
Beta
0.95
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. William J. Newell J.D. (Age 66)
    CEO & Director
    Comp: $1.07M
  • Ms. Jane Chung R.Ph. (Age 52)
    President & COO
    Comp: $934.64k
  • Dr. James R. Swartz DSc
    Ph.D., Sc.D., Founder
  • Mr. Edward C. Albini M.B.A (Age 66)
    CFO & Secretary
    Comp: $596.4k
  • Dr. Venkatesh Srinivasan Ph.d.
    Chief Technical Operations Officer
  • Dr. Hans-Peter Gerber Ph.D.
    Chief Scientific Officer
  • Mr. David Pauling J.D.
    M.A., General Counsel
  • Ms. Linda A. Fitzpatrick (Age 67)
    Chief People & Communications Officer
    Comp: $595.79k
  • Dr. Nicki Vasquez Ph.D. (Age 61)
    Chief Portfolio Strategy & Alliance Officer
  • Dr. Anne Elizabeth Borgman-Hagey M.D. (Age 55)
    Chief Medical Officer

STRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price target for 2024?

7 brokers have issued twelve-month price objectives for Sutro Biopharma's shares. Their STRO share price targets range from $8.00 to $18.00. On average, they anticipate the company's stock price to reach $12.57 in the next twelve months. This suggests a possible upside of 246.3% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How have STRO shares performed in 2024?

Sutro Biopharma's stock was trading at $4.29 at the start of the year. Since then, STRO shares have decreased by 15.4% and is now trading at $3.63.
View the best growth stocks for 2024 here
.

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our STRO earnings forecast
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) posted its earnings results on Monday, March, 25th. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of ($0.82) by $1.24. The firm had revenue of $113.72 million for the quarter, compared to analyst estimates of $12.16 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 71.42% and a negative net margin of 69.47%.

What ETFs hold Sutro Biopharma's stock?

ETFs with the largest weight of Sutro Biopharma (NASDAQ:STRO) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Simplify Propel Opportunities ETF (SURI).

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

Sutro Biopharma (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STRO) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners